| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.092 | 0.1 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.12 | 0.1 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.1 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | -0.061 | 0.1 |
| mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.086 | 0.1 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.1 |
| mRNA | Bleomycin | CTRPv2 | pan-cancer | AAC | -0.063 | 0.1 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.095 | 0.1 |